Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis open-label extension after ATTRibute-CM
2024-515092-36-00Phase 3Authorised
- Sponsor
- Eidos Therapeutics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Eidos Therapeutics. Primary endpoint: Safety. Planned start Feb 2022; status: authorised.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2024-515092-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515092-36-00.